A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

“We have run out of chemotherapy options for this patient, so we have referred them for surgical evaluation to see if cytoreductive surgery and HIPEC is an option.” Clearly not all patients with PM ...

Amber and her family in the Volkswagen convertible she bought after learning she was cancer-free Amber used to live her life with anxiety and fear—always trying to stay within her comfort zone. She ...

CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...

Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...

Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy Compared with CRSa, CRS-HIPEC improved ...

CHICAGO — Intraperitoneal (IP) chemotherapy is now an alternative to intravenous (IV) administration that "must be discussed" for women with cytoreduced ovarian cancer, several experts said here at ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

FOX CHASE (WPVI) -- HIPEC is an often overlooked form of chemotherapy, with a long track record. It's improving survival rates in some abdominal cancers, however, some patients and doctors may not ...

TAMPA, Fla. — A new study of a cancer treatment called HIPEC, heated intraperitoneal chemotherapy, is showing good results when it comes to treating women with metastatic epithelial ovarian cancer.

ROCHESTER, Minn. — Mayo Clinic researchers used a new approach to chemotherapy to more than double the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer ...